360 related articles for article (PubMed ID: 17917618)
21. Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?
Hermosillo AJ; Spinler SA
Ann Pharmacother; 2008 Jun; 42(6):790-805. PubMed ID: 18477734
[TBL] [Abstract][Full Text] [Related]
22. Improving outcomes with antiplatelet therapies in percutaneous coronary intervention and stenting.
Hobson A; Curzen N
Thromb Haemost; 2009 Jan; 101(1):23-30. PubMed ID: 19132185
[No Abstract] [Full Text] [Related]
23. Antiplatelet therapy in percutaneous coronary intervention: a critical review of the 2007 AHA/ACC/SCAI guidelines and beyond.
Cohen M
Catheter Cardiovasc Interv; 2009 Oct; 74(4):579-97. PubMed ID: 19472347
[TBL] [Abstract][Full Text] [Related]
24. Clopidogrel loading doses and outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes.
Wang C; Kereiakes DJ; Bae JP; McCollam P; He J; Griffin B
J Invasive Cardiol; 2007 Oct; 19(10):431-6. PubMed ID: 17906345
[TBL] [Abstract][Full Text] [Related]
25. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Yusuf S; Zhao F; Mehta SR; Chrolavicius S; Tognoni G; Fox KK;
N Engl J Med; 2001 Aug; 345(7):494-502. PubMed ID: 11519503
[TBL] [Abstract][Full Text] [Related]
26. Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Beinart SC; Kolm P; Veledar E; Zhang Z; Mahoney EM; Bouin O; Gabriel S; Jackson J; Chen R; Caro J; Steinhubl S; Topol E; Weintraub WS
J Am Coll Cardiol; 2005 Sep; 46(5):761-9. PubMed ID: 16139122
[TBL] [Abstract][Full Text] [Related]
27. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study.
Peters RJ; Mehta SR; Fox KA; Zhao F; Lewis BS; Kopecky SL; Diaz R; Commerford PJ; Valentin V; Yusuf S;
Circulation; 2003 Oct; 108(14):1682-7. PubMed ID: 14504182
[TBL] [Abstract][Full Text] [Related]
28. Bleeding risk associated with 1 year of dual antiplatelet therapy after percutaneous coronary intervention: Insights from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial.
Aronow HD; Steinhubl SR; Brennan DM; Berger PB; Topol EJ;
Am Heart J; 2009 Feb; 157(2):369-74. PubMed ID: 19185647
[TBL] [Abstract][Full Text] [Related]
29. Use of and inhospital outcomes after early clopidogrel therapy in patients not undergoing an early invasive strategy for treatment of non-ST-segment elevation myocardial infarction: results from Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the American College of Cardiology/American Heart Association guidelines (CRUSADE).
Alexander D; Ou FS; Roe MT; Pollack CV; Ohman EM; Cannon CP; Gibler WB; Fintel DJ; Peterson ED; Brown DL;
Am Heart J; 2008 Sep; 156(3):606-12. PubMed ID: 18760147
[TBL] [Abstract][Full Text] [Related]
30. Clopidogrel in addition to aspirin reduces one-year major adverse cardiac and cerebrovascular events in unselected patients with non-ST segment elevation myocardial infarction.
Zeymer U; Gitt AK; Zahn R; Jünger C; Bauer T; Köth O; Heer T; Wienbergen H; Gottwik M; Senges J
Acute Card Care; 2008; 10(1):43-8. PubMed ID: 17924233
[TBL] [Abstract][Full Text] [Related]
31. Evolving perspectives on clopidogrel in the treatment of ischemic stroke.
Gorelick P; Sechenova O; Hennekens CH
J Cardiovasc Pharmacol Ther; 2006 Dec; 11(4):245-8. PubMed ID: 17220470
[TBL] [Abstract][Full Text] [Related]
32. Clopidogrel in interventional cardiology: questions answered and questions remaining.
Nikhil JY; Radhakrishnan S; Paradiso-Hardy FL; Cohen EA
Can J Cardiol; 2002 Jul; 18(7):739-48. PubMed ID: 12167961
[TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance [CHARISMA] trial).
Dasgupta A; Steinhubl SR; Bhatt DL; Berger PB; Shao M; Mak KH; Fox KA; Montalescot G; Weber MA; Haffner SM; Dimas AP; Steg PG; Topol EJ;
Am J Cardiol; 2009 May; 103(10):1359-63. PubMed ID: 19427428
[TBL] [Abstract][Full Text] [Related]
34. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
[TBL] [Abstract][Full Text] [Related]
35. Pro: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regime in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'.
Rubboli A; Halperin JL
Thromb Haemost; 2008 Nov; 100(5):752-3. PubMed ID: 18989515
[No Abstract] [Full Text] [Related]
36. A high maintenance dose of clopidogrel improves short-term clinical outcomes in patients with acute coronary syndrome undergoing drug-eluting stent implantation.
Han YL; Wang B; Li Y; Xu K; Wang SL; Jing QM; Wang ZL; Wang DM; Ma YY; Wang G
Chin Med J (Engl); 2009 Apr; 122(7):793-7. PubMed ID: 19493391
[TBL] [Abstract][Full Text] [Related]
37. Randomized trial comparing 600- with 300-mg loading dose of clopidogrel in patients with non-ST elevation acute coronary syndrome undergoing percutaneous coronary intervention: results of the Platelet Responsiveness to Aspirin and Clopidogrel and Troponin Increment after Coronary intervention in Acute coronary Lesions (PRACTICAL) Trial.
Yong G; Rankin J; Ferguson L; Thom J; French J; Brieger D; Chew DP; Dick R; Eccleston D; Hockings B; Walters D; Whelan A; Eikelboom JW
Am Heart J; 2009 Jan; 157(1):60.e1-9. PubMed ID: 19081397
[TBL] [Abstract][Full Text] [Related]
38. Effects of pretreatment with clopidogrel on nonemergent percutaneous coronary intervention after fibrinolytic administration for ST-segment elevation myocardial infarction: a Clopidogrel as Adjunctive Reperfusion Therapy-Thrombolysis in Myocardial Infarction (CLARITY-TIMI) 28 study.
Gibson CM; Murphy SA; Pride YB; Kirtane AJ; Aroesty JM; Stein EB; Ciaglo LN; Southard MC; Sabatine MS; Cannon CP; Braunwald E;
Am Heart J; 2008 Jan; 155(1):133-9. PubMed ID: 18082504
[TBL] [Abstract][Full Text] [Related]
39. Contra: 'Antithrombotic therapy with warfarin, aspirin and clopidogrel is the recommended regimen in anticoagulated patients who present with an acute coronary syndrome and/or undergo percutaneous coronary interventions'. Not for everybody.
Roldán V; Marín F
Thromb Haemost; 2008 Nov; 100(5):754-5. PubMed ID: 18989516
[No Abstract] [Full Text] [Related]
40. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
Toth PP
Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
